o(6)-benzylguanine has been researched along with Brain Stem Neoplasms in 1 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
Brain Stem Neoplasms: Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated with the combination of O6-benzylguanine (O6BG) and temozolomide(®) (TMZ)." | 9.16 | A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. ( Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE, 2012) |
| "To estimate the sustained (≥8 weeks) objective response rate in pediatric patients with recurrent or progressive high-grade gliomas (HGG, Stratum A) or brainstem gliomas (BSG, Stratum B) treated with the combination of O6-benzylguanine (O6BG) and temozolomide(®) (TMZ)." | 5.16 | A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. ( Balis, FM; Berg, SL; Boyett, JM; Geyer, JR; Goldman, S; Gururangan, S; Kun, LE; McLendon, RE; Minturn, JE; Packer, RJ; Pollack, IF; Poussaint, TY; Wallace, D; Warren, KE, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Warren, KE | 1 |
| Gururangan, S | 1 |
| Geyer, JR | 1 |
| McLendon, RE | 1 |
| Poussaint, TY | 1 |
| Wallace, D | 1 |
| Balis, FM | 1 |
| Berg, SL | 1 |
| Packer, RJ | 1 |
| Goldman, S | 1 |
| Minturn, JE | 1 |
| Pollack, IF | 1 |
| Boyett, JM | 1 |
| Kun, LE | 1 |
1 trial available for o(6)-benzylguanine and Brain Stem Neoplasms
| Article | Year |
|---|---|
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Dacarbazine; DNA M | 2012 |